Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation

By sjmartinez • July 25, 2022

Mao Z, Nesterenko PA, McLaughlin J, Deng W, Burton Sojo G, Cheng D, Noguchi M, Chour W, DeLucia DC, Finton KA, Qin Y, Obusan MB, Tran W, Wang L, Bangayan NJ, Ta L, Chen CC, Seet CS, Crooks GM, Phillips JW, Heath JR, Strong RK, Lee JK, Wohlschlegel JA, Witte ON. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation. Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2203410119. doi: 10.1073/pnas.2203410119. Epub 2022 Jul 25. PMID: 35878026.

Tags: Hematology/Oncology, immunopeptidome, major histocompatibility complexes, MHC, prostate cancer, prostatic acid phosphatase, Publications, T cell receptor, TCR

Related Posts

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat[...]

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo[...]

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]